EMA Authorised: Enyglid (repaglinide) — Krka, d.d., Novo mesto

View source ↗

Summary

Enyglid (repaglinide) by Krka has been authorized in the EU for the treatment of type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Enyglid (repaglinide)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Krka, d.d., Novo mesto. Decision date: 27/01/2025